Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Investments at Fair Value (Tables)

Investments at Fair Value (Tables)

9 Months Ended

Sep. 30, 2015

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following tables classify into the fair value hierarchy financial instruments measured at fair value on a recurring basis in the accompanying condensed consolidated balance sheets as of September 30, 2015 (unaudited) and December 31, 2014:

	Fair Value Measurement as of September 30, 2015
($ in thousands)	Level 1		Level 2		Level 3		Total
Assets
Marketable securities:
U.S. treasury bills	$	39,951	$	-	$	-	$	39,951
Total marketable securities		39,951		-		-		39,951
Long-term investments, at fair value		-		-		4,095		4,095
Total	$	39,951	$	-	$	4,095	$	44,046

	Fair Value Measurement as of December 31, 2014
($ in thousands)	Level 1		Level 2		Level 3		Total
Assets
Marketable securities:
U.S. treasury bills	$	19,998	$	-	$	-	$	19,998
Mutual funds		4		-				4
Total marketable securities		20,002		-		-		20,002
Long-term investments, at fair value		-		-		4,160		4,160
Total	$	20,002	$	-	$	4,160	$	24,162

Schedule of changes in fair value of financial instruments

The table below provides a roll-forward of the changes in fair value of Level 3 financial instruments, as of September 30, 2015:

	Fair Value of Investment
	Short-term		Long-term				Total
($ in thousands)	Other		Other		CB Pharma
Balance at December 31, 2014	$	-	$	250	$	3,910	$	4,160
Change in fair value of investment		-		-		(65)		(65)
Balance at September 30, 2015	$	-	$	250	$	3,845	$	4,095